Immuno Oncology Clinical Trials Market Revenue Forecast to 2032

Global immuno oncology clinical trials revenue is projected to reach $21.4 billion, supported by expanding biomarker driven designs and diversified oncology indications. A sustained 12.1% annual growth rate reflects increasing trial complexity, rising outsourcing intensity, and broader access to precision immunotherapies worldwide.

Prepared by Stat-Signal Research Team